Literature DB >> 26780886

Microaneurysms in renal angiomyolipomas: Can clinical and computed tomography features predict their presence and size?

J Champagnac1, C Melodelima2, T Martinelli3, G Pagnoux1, L Badet4, L Juillard5, O Rouvière6.   

Abstract

PURPOSE: To evaluate clinical and multidetector computed tomography (MDCT) features associated with the presence and size of microaneurysms in renal angiomyolipomas (AMLs).
MATERIALS AND METHODS: The MDCTs and digital subtraction angiographies (DSAs) of 31 patients who had further percutaneous arterial embolization of AMLs were retrospectively reviewed. They were 22 women and 9 men (mean age, 47.7±27.7 years). The medical files of the included patients were reviewed for age, gender and clinical features. MDCT and DSA images were analyzed by two readers working in consensus.
RESULTS: Of the 31 patients, 15 had tuberous sclerosis complex (TSC) or lymphangioleiomyomatosis (LAM). In total, the 31 patients had 54 AMLs (5 ruptured). On DSA, 28 clusters of microaneurysms were found in 17 patients (21 AMLs). Four of the five ruptured AMLs had microaneurysms. None of the 12 AMLs≤40mm and 21 of the 42 AMLs>40mm had microaneurysms. Among AMLs>40mm, history of TSC/LAM (P=0.5), RENAL score (P=0.7) and relative volume of fat (P=0.11) did not significantly predict the presence of microaneurysms. Microaneurysms were significantly larger in ruptured (9.5±5.7mm) than non-ruptured (3.9±1.9mm, P=0.02) AMLs. No associations were found between the size of microaneurysms and the size of AMLs.
CONCLUSION: Microaneurysms were found in no AML ≤40mm and in 50%of AMLs>40mm. In AMLs >40mm, history of TSC/LAM, RENAL score and relative volume of fat did not significantly predict the presence of microaneurysms.
Copyright © 2016. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Computed tomography; Digital subtraction angiography; Microaneurysm; Renal angiomyolipoma

Mesh:

Year:  2016        PMID: 26780886     DOI: 10.1016/j.diii.2015.12.004

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  7 in total

1.  Surveillance imaging for sporadic renal angiomyolipoma less than 40 mm: lessons learnt and recommendations from the experience of a large district general hospital.

Authors:  K E Chan; Ecp Chedgy; C L Bent; K J Turner
Journal:  Ann R Coll Surg Engl       Date:  2018-04-16       Impact factor: 1.891

2.  Evaluation of ABO blood groups and blood-based biomarkers as a predictor of growth kinetics of renal angiomyolipoma.

Authors:  Burak Arslan; Okan Gürkan; Bugra Çetin; Öykü Aksoy Arslan; Taha Göv; Gökhan Yazıcı; Tolga Eroglu; Mustafa Asım Avcı; Enver Ozdemir
Journal:  Int Urol Nephrol       Date:  2018-10-15       Impact factor: 2.370

3.  Selective arterial embolization of renal angiomyolipomas: A 10-year experience.

Authors:  Guram Nozadze; Signe Benzon Larsen; Søren Heerwagen; Ruben Juhl Jensen; Lars Lönn; Martin Andreas Røder
Journal:  BJUI Compass       Date:  2021-08-31

4.  Renal manifestations of tuberous sclerosis complex: patients' and parents' knowledge and routines for renal follow-up - a questionnaire study.

Authors:  I Cockerell; M Guenin; K Heimdal; M Bjørnvold; K K Selmer; O Rouvière
Journal:  BMC Nephrol       Date:  2018-02-13       Impact factor: 2.388

Review 5.  The Risks of Renal Angiomyolipoma: Reviewing the Evidence.

Authors:  Raouf M Seyam; Waleed K Alkhudair; Said A Kattan; Mohamed F Alotaibi; Hassan M Alzahrani; Waleed M Altaweel
Journal:  J Kidney Cancer VHL       Date:  2017-10-16

6.  Lymphangioleiomyomatosis Associated with Tuberous Sclerosis Complex.

Authors:  Keizo Tanitame
Journal:  Intern Med       Date:  2020-07-14       Impact factor: 1.271

Review 7.  New Trends and Evidence for the Management of Renal Angiomyolipoma: A Comprehensive Narrative Review of the Literature.

Authors:  Juan Camilo Álvarez Restrepo; David Andres Castañeda Millan; Carlos Andres Riveros Sabogal; Andres Felipe Puentes Bernal; Wilfredo Donoso Donoso
Journal:  J Kidney Cancer VHL       Date:  2022-01-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.